Neuroendocrine Tumor Treatment

Neuroendocrine Tumor Treatment: Advances And New Options


Neuroendocrine tumors (NETs) are a rare type of cancer that starts in the neuroendocrine cells of the body. These cells are found throughout the body in organs like the lungs, pancreas, colon, and stomach. While NETs pose unique treatment challenges due to their diverse nature, significant advances have been made in recent years to improve outcomes for patients.

Types of NETs and Staging

NETs are categorized based on the organ or tissue where they originate. The three main types are pancreatic NETs, carcinoid tumors (lung and gastrointestinal NETs), and poorly differentiated neuroendocrine carcinomas. Tumors are also classified based on how aggressive or advanced they are using a staging system. Knowing the type and stage of the NET helps doctors determine the most appropriate treatment plan.


For localized NETs without spread to lymph nodes or distant sites, surgery to remove the tumor remains the standard first-line treatment option. The goal is to remove the entire tumor along with some surrounding healthy tissue and lymph nodes. The type of surgery depends on the location and size of the tumor. For pancreatic NETs, a Whipple procedure may be required which involves removing the head of the pancreas and other tissues. Achieving clean surgical margins is important for reducing the risk of recurrence.

Medical Therapies

For NETs that cannot be completely removed or have spread, medical therapies play a key role. Some medical options include:

– Somatostatin Analogues: Drugs like octreotide and lanreotide bind to somatostatin receptors on NET cells and inhibit the release of hormones and growth factors, slowing tumor growth. They are well-tolerated and commonly used.

– Targeted Therapy: Medications like sunitinib and everolimus target specific cell signaling pathways driving Neuroendocrine Tumor Treatment growth. They have shown improved progression-free and overall survival compared to older treatments.

– Chemotherapy: Some poorly differentiated NETs may be treated with combination chemotherapy approaches like cisplatin and etoposide. The side effects are more pronounced than targeted therapies.

– Radiopeptide Therapy: Radiolabeled somatostatin analogues allow targeted internal radiation delivery. Options include lutetium-177 and yttrium-90 dotatate which have demonstrated efficacy in midgut NETs.

– Hepatic-directed Therapies: For NET liver metastases, procedures like embolization and radiofrequency ablation can be utilized in addition to medical therapies.

New Advances in Treatment

Immunotherapy and new targeted therapies expanding the treatment toolbox have shown promising results. Immunotherapy drugs help activate the body’s immune system to fight NET cells. For example, preliminary studies show pembrolizumab may benefit certain high-grade NET subgroups. Various other targeted agents are also under investigation in clinical trials. Other advances like novel surgical procedures using laparoscopy and robotic assistance enable less invasive options. Combination treatment approaches integrating different modalities are also areas of active research.

Outcome and Follow-up

With a multi-disciplinary care team approach using customized treatment plans based on risk factors and the tumor’s unique biology, outcomes for NET patients have greatly improved. While considered mainly incurable cancers, survival rates have extended and quality of life optimized. Long term follow-up involving repetitive diagnostic imaging and biochemical marker monitoring is essential after initial treatment to detect and manage recurrence at an early stage. Continued efforts to better understand NET subtypes will guide ongoing enhancements in diagnosis and personalized care.

In summary, neuroendocrine tumors present ongoing challenges but significant progress has been made thanks to collaborative research worldwide. Developing newer targeted and immune-based therapies as well as utilization of minimally invasive surgical innovations offers promise to further improve NET patient outcomes and longevity. A team-based treatment strategy customized for each individual remains key.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it